CSIMarket
 
Biora Therapeutics Inc   (NASDAQ: BIOR)
Other Ticker:  
 
 
Price: $0.2200 $0.00 0.000%
Day's High: $0.3802 Week Perf: 0.00
Day's Low: $ 0.15 30 Day Perf: -83.08 %
Volume (M): 169 52 Wk High: $ 7.90
Volume (M$): $ 37 52 Wk Avg: $5.14
Open: $0.38 52 Wk Low: $0.15



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 17
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Biora Therapeutics Inc
Biora Therapeutics Inc is a biotechnology company that specializes in developing innovative solutions for the treatment of chronic wounds. The company was founded in 1994 and is based in Malmo, Sweden. It has a global presence with offices in Europe, North America, and Asia.

The main focus of Biora Therapeutics is to develop bioactive materials that can stimulate and enhance the natural healing process of chronic wounds. These materials are designed to work in synergy with the body's own immune system and promote tissue repair and regeneration.

The company has developed several proprietary technologies that are based on the use of growth factors, collagen matrices, and other biomaterials. These technologies are designed to deliver an optimized combination of growth factors and other bioactive molecules to chronic wounds, thereby promoting faster healing and reducing the risk of infection.

Biora Therapeutics has a range of products that are used in the treatment of chronic wounds, including diabetic foot ulcers, venous ulcers, pressure ulcers, and burn injuries. The company's flagship product is Purion, a patented collagen matrix that contains a specific combination of growth factors and antimicrobial peptides. Purion is designed to stimulate wound healing while also reducing the risk of infection.

In addition to Purion, Biora Therapeutics has also developed a range of other products, including wound dressings, wound care kits, and topical gels. These products are aimed at meeting the needs of patients across a wide range of wound types and severities.

The company has a strong commitment to research and development, and invests heavily in innovative technologies and new therapeutic approaches. Biora Therapeutics works closely with leading academic and clinical research institutions to gather evidence-based data on the efficacy and safety of its products.

Overall, Biora Therapeutics is a leading innovator in the field of wound care, and its products have been shown to deliver significant benefits to patients with chronic wounds. With its strong focus on research and development, the company is well positioned to continue driving advances in this important area of healthcare.


   Company Address: 4330 La Jolla Village Drive San Diego 92122 CA
   Company Phone Number: 727-2841   Stock Exchange / Ticker: NASDAQ BIOR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARDX        3.11% 
BDRX   -3.31%    
FOLD        0.15% 
LFCR        0.32% 
OCEA   -5.25%    
ZYME        6.91% 
• View Complete Report
   



Financing Agreement

Embracing Opportunities: Biora Therapeutics Secures Funding and Athyrium Capital Management Displays Confidence in Biotech Innovations,

Published Mon, Aug 12 2024 8:05 PM UTC

Biora Therapeutics Secures Funding Agreement to Continue its Path to Pharma Partnership
In a significant milestone for Biora Therapeutics, the biotechnology company announced a new funding agreement with its existing investors, amounting to $16 million. This multiple-draw facility will serve as a crucial bridge to support the companyns anticipated pharma partnership. The...

Clinical Study

Pharmacokinetic Profile and Tissue Distribution of BT-600 Validated in Biora Therapeutics Phase 1 Clinical Trial

Published Thu, Jul 18 2024 12:00 PM UTC

Abstract: In recent developments, Biora Therapeutics has unveiled supplemental data from its Phase 1 clinical trial of BT-600, presented at a Key Opinion Leader (KOL) event. BT-600, utilizing the innovative NaviCap platform, showcased impressive ability to deliver therapeutic agents topically throughout the entire colon while maintaining low systemic concentrations. This art...

Clinical Study

that encompasses the highlights would be Biora Therapeutics BT-600 and NaviCap Platform Show Remarkable Potential in...

Published Mon, Jul 1 2024 12:00 PM UTC

Biora Therapeutics Revolutionizes Colon Delivery of Therapeutics with Positive Clinical Trial Results for BT-600 and the NaviCap PlatformBiora Therapeutics, a leading biotechnology company, recently announced positive clinical trial results for their groundbreaking product, BT-600, along with the successful completion of the Multiple-Ascending Dose (MAD) cohorts. These achie...

Clinical Study

Biora Therapeutics to Unveil Groundbreaking BioJet System Data at 2024 Summit Amid Milestone BT-600 Trial...

Published Tue, Jun 11 2024 12:00 PM UTC

Biora Therapeutics, a leader in innovative drug delivery solutions, has announced a significant milestone in its mission to revolutionize oral drug delivery systems. The company is set to present preclinical data on their cutting-edge BioJet Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit on June 19, 2024. Innovation at the ForefrontThe ...

Clinical Study

Transforming Colon Therapeutics: Biora Therapeutics' NaviCap Platform Shines in Clinical Trials

Published Mon, May 20 2024 12:01 PM UTC

Revolutionizing Colon Therapeutics: Biora Therapeutics NaviCap Platform Shows Promising Clinical ResultsBiora Therapeutics, a pioneering healthcare company, recently presented clinical data at Digestive Disease Week 2024, highlighting the remarkable device function of their groundbreaking NaviCap Platform. Four device performance studies conducted by the company demonstrat...







Biora Therapeutics Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com